Completed PHASE3 INTERVENTIONAL 3-arm NCT00800267

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

A 6-month, Randomized, Double-masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Glaucoma Ocular Hypertension

Interventions fixed combination latanoprost-timolol latanoprost 0.005% timolol 0.5%

Updated 9 times since 2017 Last updated: Feb 17, 2021 Started: Jul 31, 1997 Primary completion: Jun 30, 1999 Completion: Jun 30, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00800267, this PHASE3 trial focuses on Glaucoma and Ocular Hypertension and remains completed. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 9 times since 1997, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Mar 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Boston, United States , Boulder, United States , Charleston, United States , Charlotte, United States , Charlottesville, United States , Chicago, United States and 32 more locations